LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

43.29 -0.51

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

42.61

Max

43.85

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+27.73% upside

Turustatistika
By TradingEconomics
Turukapital	211M 3.4B
Eelmine avamishind	43.8
Eelmine sulgemishind	43.29

Uudiste sentiment

By Acuity

34%

66%

116 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2025, 22:02 UTC

Tulu

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10. dets 2025, 21:46 UTC

Tulu

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10. dets 2025, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10. dets 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10. dets 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10. dets 2025, 23:20 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10. dets 2025, 23:15 UTC

Tulu

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10. dets 2025, 22:59 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10. dets 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10. dets 2025, 22:40 UTC

Tulu

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. dets 2025, 22:06 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. dets 2025, 22:02 UTC

Tulu

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. dets 2025, 22:00 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10. dets 2025, 21:53 UTC

Tulu

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. dets 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10. dets 2025, 21:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

10. dets 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10. dets 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. dets 2025, 21:33 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10. dets 2025, 21:32 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10. dets 2025, 21:25 UTC

Tulu

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. dets 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10. dets 2025, 21:16 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10. dets 2025, 21:15 UTC

Tulu

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10. dets 2025, 21:14 UTC

Tulu

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10. dets 2025, 21:14 UTC

Tulu

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

27.73% tõus

12 kuu keskmine prognoos

Keskmine 55.59 USD 27.73%

Kõrge 65 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

116 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.